CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Qualitative and Mixed Methods Provide Unique Contributions to Outcomes Research Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation The mSToPS Randomized Clinical Trial Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization Percutaneous coronary intervention using a combination of robotics and telecommunications by an operator in a separate physical location from the patient: an early exploration into the feasibility of telestenting (the REMOTE-PCI study) Qualitative Methodology in Cardiovascular Outcomes Research: A Contemporary Look Syncope After Percutaneous Coronary Intervention 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology Screening for Atrial Fibrillation With Electrocardiography US Preventive Services Task Force Recommendation Statement

Review ArticleVolume 70, Issue 17, October 2017, Pages 2171-2185

JOURNAL:J Am Coll Cardiol. Article Link

How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD

Hong KN, Fuster V, Bhatt DL et al. Keywords: cardiovascular disease; diabetes; hyperlipidemia; hypertension; primary prevention

ABSTRACT

Diabetes, hyperlipidemia, and hypertension are modifiable risk factors that predict cardiovascular disease events. The effect of these risk factors on incident cardiovascular disease increases with progressively higher levels of glucose, low-density lipoprotein cholesterol, and blood pressure. The thresholds for initiating treatment of these modifiable risk factors and the optimal goals of risk factor modification are a focus of primary prevention research. Although an aggressive approach is appealing, adverse events may occur, and potential physiological barriers may exist. This paper discusses primary prevention of coronary heart disease that may be achieved through modification of diabetes, hyperlipidemia, and hypertension by summarizing current guidelines and pertinent clinical trial data from intervention trials that included a primary prevention cohort.